BRAF and acute myeloid leukemia: Specifically, when evaluating the role of BRAF mutations in AML progression, it was found that compared to patients with de novo AML or those with secondary AML without BRAF mutations, patients with BRAF mutations showed an incredibly poor prognosis, with a median survival of 126 days (range: 2–290 days, p = 0.0012) [7].